| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Carolina Herrera | Q116679881 |
| P2860 | cites work | First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy | Q21135264 |
| Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis | Q21144588 | ||
| Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research | Q24651042 | ||
| HIV Drug Resistance: Problems and Perspectives | Q26864534 | ||
| μOrgano: A Lego®-Like Plug & Play System for Modular Multi-Organ-Chips | Q27315172 | ||
| New candidate biomarkers in the female genital tract to evaluate microbicide toxicity | Q27334382 | ||
| Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery | Q28081272 | ||
| Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche | Q28239639 | ||
| HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy | Q28339571 | ||
| In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide | Q28472968 | ||
| Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel | Q28473376 | ||
| Global expression of molecular transporters in the human vaginal tract: implications for HIV chemoprophylaxis | Q28534412 | ||
| Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study | Q28544439 | ||
| Expression of Genes for Drug Transporters in the Human Female Genital Tract and Modulatory Effect of Antiretroviral Drugs | Q28548592 | ||
| Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype | Q28646874 | ||
| Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. | Q29619254 | ||
| Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay | Q29619255 | ||
| Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. | Q29622903 | ||
| Formulation, pharmacokinetics and pharmacodynamics of topical microbicides | Q30412592 | ||
| Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid | Q32165620 | ||
| Restricted expression of human T-cell leukemia--lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes | Q42822749 | ||
| Microbicide trial screeches to a halt | Q42841576 | ||
| Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue | Q43565951 | ||
| Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults | Q44109830 | ||
| Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives | Q44884891 | ||
| Formulation and transport properties of tenofovir loaded liposomes through Caco-2 cell model | Q45366387 | ||
| Antigens Encoded by the 3′-Terminal Region of Human T-Cell Leukemia Virus: Evidence for a Functional Gene | Q45807592 | ||
| Antiretroviral-drug resistance among patients recently infected with HIV. | Q46277555 | ||
| Prospects for passive immunity to prevent HIV infection | Q46621371 | ||
| A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection | Q46736849 | ||
| In vitro enteroid-derived three-dimensional tissue model of human small intestinal epithelium with innate immune responses | Q47109988 | ||
| Microphysiologic systems in female reproductive biology | Q47600086 | ||
| In Silico and in Vitro Screening for P-Glycoprotein Interaction with Tenofovir, Darunavir, and Dapivirine: An Antiretroviral Drug Combination for Topical Prevention of Colorectal HIV Transmission | Q48059033 | ||
| MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption. | Q48145638 | ||
| Vascularized and functional human liver from an iPSC-derived organ bud transplant. | Q48453997 | ||
| Development of a primary human Small Intestine-on-a-Chip using biopsy-derived organoids. | Q49504268 | ||
| Use of frozen-thawed cervical tissues in the organ culture system to measure anti-HIV activities of candidate microbicides. | Q50110975 | ||
| CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic | Q37191866 | ||
| Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention | Q37258271 | ||
| Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue | Q37258298 | ||
| Short communication: expression of transporters and metabolizing enzymes in the female lower genital tract: implications for microbicide research | Q37258318 | ||
| Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection | Q37273158 | ||
| Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. | Q37275060 | ||
| Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women | Q37362444 | ||
| HIV infection of the genital mucosa in women. | Q37370910 | ||
| Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis | Q37410434 | ||
| A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains | Q37410812 | ||
| Cell-mediated immunity to HIV in the female reproductive tract | Q37456785 | ||
| In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission | Q37568492 | ||
| Pharmacokinetics and drug-drug interactions of antiretrovirals: an update | Q37576490 | ||
| The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters | Q37651953 | ||
| Vaginal microbicides to prevent human immunodeficiency virus infection in women: perspectives on the female genital tract, sexual maturity and mucosal inflammation | Q37994918 | ||
| Candidate microbicides and their mechanisms of action | Q38101262 | ||
| Inflammation and HIV Transmission in Sub-Saharan Africa | Q38422546 | ||
| Sensing of HIV-1 Infection in Tzm-bl Cells with Reconstituted Expression of STING. | Q38812549 | ||
| Drug transporter gene expression in human colorectal tissue and cell lines: modulation with antiretrovirals for microbicide optimization. | Q38823939 | ||
| Vaginal expression of efflux transporters and the potential impact on the disposition of microbicides in vitro and in rabbits. | Q38946716 | ||
| Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity | Q39015851 | ||
| Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells | Q39017459 | ||
| HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1. | Q39033850 | ||
| Human intestinal lamina propria lymphocytes are naturally permissive to HIV-1 infection. | Q39160304 | ||
| Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. | Q39165804 | ||
| Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions | Q39229674 | ||
| The Effect of Commonly Used Excipients on the Epithelial Integrity of Human Cervicovaginal Tissue | Q39407355 | ||
| A dual chamber model of female cervical mucosa for the study of HIV transmission and for the evaluation of candidate HIV microbicides | Q39550855 | ||
| Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. | Q39551934 | ||
| Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120 | Q39612212 | ||
| The impact of pregnancy on anti-HIV activity of cervicovaginal secretions | Q39619969 | ||
| Impact of drug transporters on cellular resistance towards saquinavir and darunavir | Q39659414 | ||
| The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities | Q39686664 | ||
| Preventing HIV infection without targeting the virus: how reducing HIV target cells at the genital tract is a new approach to HIV prevention | Q40047164 | ||
| Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women | Q40176907 | ||
| The future of HIV prevention: prospects for an effective anti-HIV microbicide. | Q40213117 | ||
| Comparison of Mucosal Markers of Human Immunodeficiency Virus Susceptibility in Healthy Premenopausal Versus Postmenopausal Women | Q40248406 | ||
| Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305). | Q40464768 | ||
| Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis | Q40510608 | ||
| Transporters for Antiretroviral Drugs in Colorectal CD4+ T Cells and Circulating α4β7 Integrin CD4+ T Cells: Implications for HIV Microbicides. | Q40596923 | ||
| Specific Antibody Responses to Vaccination with Bivalent CM235/SF2 gp120: Detection of Homologous and Heterologous Neutralizing Antibody to Subtype E (CRF01.AE) HIV Type 1 | Q40621694 | ||
| Reduced levels of genital tract immune biomarkers in postmenopausal women: implications for HIV acquisition | Q40736441 | ||
| Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates. | Q40800869 | ||
| Classification of human colorectal adenocarcinoma cell lines | Q41062939 | ||
| Confocal fluorescence microscopy: An ultra-sensitive tool used to evaluate intracellular antiretroviral nano-drug delivery in HeLa cells | Q41084513 | ||
| Absence of HeLa cell contamination in 169 cell lines derived from human tumors | Q41761715 | ||
| Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro | Q41770080 | ||
| Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives | Q42211960 | ||
| Correction: Seminal plasma induces inflammation and enhances HIV-1 replication in human cervical tissue explants | Q42333108 | ||
| Fluorescence and electron microscopy to visualize the intracellular fate of nanoparticles for drug delivery | Q42431249 | ||
| Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model | Q42503397 | ||
| Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid | Q33227608 | ||
| Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides | Q33260514 | ||
| Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine | Q33358999 | ||
| Seminal plasma induces inflammation and enhances HIV-1 replication in human cervical tissue explants | Q33390855 | ||
| Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies | Q33627673 | ||
| A vaginal fluid simulant | Q33653706 | ||
| Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. | Q33693391 | ||
| Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention | Q33769971 | ||
| Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides | Q33805787 | ||
| A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. | Q33808638 | ||
| Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis | Q33821257 | ||
| A comparative proteomic analysis of the soluble immune factor environment of rectal and oral mucosa | Q33825756 | ||
| Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production | Q33827798 | ||
| A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. | Q33853988 | ||
| Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention | Q33888718 | ||
| Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis | Q33988153 | ||
| Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission | Q34034418 | ||
| Productive HIV-1 infection of human cervical tissue ex vivo is associated with the secretory phase of the menstrual cycle. | Q34127684 | ||
| In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories | Q34352144 | ||
| A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate | Q34414539 | ||
| Expression and localization of p-glycoprotein, multidrug resistance protein 4, and breast cancer resistance protein in the female lower genital tract of human and pigtailed macaque | Q34420654 | ||
| A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007). | Q34661892 | ||
| Anti-HIV-1 activity of flavonoid myricetin on HIV-1 infection in a dual-chamber in vitro model. | Q34784838 | ||
| Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. | Q34834065 | ||
| Glycerol monolaurate prevents mucosal SIV transmission | Q34957016 | ||
| Selective transmission of R5 HIV-1 variants: where is the gatekeeper? | Q35018140 | ||
| Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom | Q35075694 | ||
| Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. | Q35077568 | ||
| Innate immunity in the vagina (Part II): Anti-HIV activity and antiviral content of human vaginal secretions | Q35078336 | ||
| Cultivated vaginal microbiomes alter HIV-1 infection and antiretroviral efficacy in colonized epithelial multilayer cultures | Q35133798 | ||
| HIV-1 infection of human penile explant tissue and protection by candidate microbicides | Q35148241 | ||
| Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters | Q35385630 | ||
| A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study). | Q35571216 | ||
| Monoclonal and Single Domain Antibodies Targeting β-Integrin Subunits Block Sexual Transmission of HIV-1 in In Vitro and In Vivo Model Systems | Q35591504 | ||
| Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies. | Q51417311 | ||
| Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. | Q51541144 | ||
| Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women. | Q52685409 | ||
| CONTINUOUS CULTURE OF HUMAN LYMPHOBLASTS FROM PERIPHERAL BLOOD OF A CHILD WITH ACUTE LEUKEMIA. | Q52828546 | ||
| Studies of the growth and cytogenetic properties of human endometrial adenocarcinoma in culture and its development into an established line | Q52831160 | ||
| Some properties of a new epithelial cell line of human origin. | Q52832927 | ||
| Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. | Q52965935 | ||
| French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. | Q53276114 | ||
| MRP2 Inhibition by HIV Protease Inhibitors in Rat and Human Hepatocytes: A Quantitative Confocal Microscopy Study. | Q53703256 | ||
| Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes. | Q53882650 | ||
| Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. | Q54059737 | ||
| Comparative Assessment of Small and Large Intestine Biopsies for Ex Vivo HIV-1 Pathogenesis Studies. | Q54239255 | ||
| Detection, quantification, and characterisation of HIV/SIV. | Q54399618 | ||
| Synthetic cervical mucus formulation | Q56765936 | ||
| Brief summary of the current protocols for generating intestinal organoids | Q57171935 | ||
| Development of an in vitro organ culture model to study transmissionof HIV-1 in the female genital tract | Q57369522 | ||
| Diversity of vaginal microbiota in sub-Saharan Africa and its effects on HIV transmission and prevention | Q57469974 | ||
| Characterization of the Genital Mucosa Immune Profile to Distinguish Phases of the Menstrual Cycle: Implications for HIV Susceptibility | Q58088897 | ||
| Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides | Q61312701 | ||
| Epithelial Cells and Fibroblasts from the Human Female Reproductive Tract Accumulate and Release TFV and TAF to Sustain Inhibition of HIV Infection of CD4+ T cells | Q61796692 | ||
| Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics | Q63361759 | ||
| STUDIES ON SUCCINATE-TETRAZOLIUM REDUCTASE SYSTEMS. III. POINTS OF COUPLING OF FOUR DIFFERENT TETRAZOLIUM SALTS | Q76640750 | ||
| Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells | Q79844072 | ||
| The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM | Q90583050 | ||
| Organ-on-chip models: Implications in drug discovery and clinical applications | Q93167893 | ||
| Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue | Q35665851 | ||
| Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. | Q35759112 | ||
| Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. | Q35839936 | ||
| Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection | Q35842299 | ||
| Molecular Signatures of Immune Activation and Epithelial Barrier Remodeling Are Enhanced during the Luteal Phase of the Menstrual Cycle: Implications for HIV Susceptibility | Q35913894 | ||
| Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide | Q35941336 | ||
| Expression Profile of Human Fc Receptors in Mucosal Tissue: Implications for Antibody-Dependent Cellular Effector Functions Targeting HIV-1 Transmission. | Q36013396 | ||
| Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials | Q36083337 | ||
| Reformulated tenofovir gel for use as a dual compartment microbicide. | Q36159765 | ||
| Saquinavir inhibits early events associated with establishment of HIV-1 infection: potential role for protease inhibitors in prevention | Q36171647 | ||
| Use of human tissue explants to study human infectious agents | Q36189818 | ||
| Three-dimensional analysis of budding sites and released virus suggests a revised model for HIV-1 morphogenesis | Q36266587 | ||
| Sensitive and rapid assay on MT-4 cells for detection of antiviral compounds against the AIDS virus | Q36283746 | ||
| Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission | Q36353342 | ||
| Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study | Q36358774 | ||
| Genital tract viral load in HIV Type 1-positive women correlates with specific cytokine levels in cervical-vaginal secretions but is not a determinant of infectious virus or anti-HIV activity | Q36358905 | ||
| Nonreproducibility of "snap-frozen" rectal biopsies for later use in ex vivo explant infectibility studies | Q36359000 | ||
| RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate | Q36359092 | ||
| Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue | Q36399466 | ||
| Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention | Q36409617 | ||
| Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel | Q36446138 | ||
| Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. | Q36593791 | ||
| Innate and adaptive anti-HIV immune responses in the female reproductive tract | Q36637034 | ||
| Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis. | Q36644606 | ||
| Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues | Q36756170 | ||
| Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. | Q36793483 | ||
| Distinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue | Q36888077 | ||
| Comparison of Follicular and Luteal Phase Mucosal Markers of HIV Susceptibility in Healthy Women | Q36966645 | ||
| Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor | Q37072072 | ||
| Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination | Q37119451 | ||
| Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues | Q37123335 | ||
| Apples and oranges? Interpreting success in HIV prevention trials | Q37178472 | ||
| Reverse transcriptase inhibitors as potential colorectal microbicides | Q37190754 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | pharmacodynamics | Q725307 |
| P304 | page(s) | 578 | |
| P577 | publication date | 2019-05-24 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | The Pre-clinical Toolbox of Pharmacokinetics and Pharmacodynamics: in vitro and ex vivo Models. | |
| P478 | volume | 10 |
Search more.